August 27th 2024
Vials of tirzepatide 2.5 mg and 5 mg will be available at a 50% discount compared with the list price of other incretin-based obesity medications.
August 21st 2024
A detailed report of study findings will be published in a peer-reviewed journal and presented at ObesityWeek 2024.
Timothy Mackey, MAS, PhD, discusses a study that sought to determine the risk of sourcing semaglutide from online platforms.
August 8th 2024
With the high demand in GLP-1 medications, pharmacists are now living in an unprecedented time of filling prescriptions for high-cost brand-name drugs.
August 4th 2024
As clinical research continues, investigators are learning more about how GLP-1 drugs modify cardiovascular risks.
Q&A: Examining the Key Drivers of a Healthful Lifestyle
Lifestyle changes—including eating fruits, vegetables, and whole grains—can help patients, especially those with diabetes or hypertension, improve outcomes.
A Deeper Understanding of GLP-1 Mechanism of Action Will Open Doors for Future Uses
GLP-1 therapies are being evaluated to treat cardiovascular and kidney diseases in individuals with overweight or obesity.
Q&A: Understanding Benefits, Managing Adverse Effects of GLP-1 Receptor Agonists
These therapies are highly beneficial, but can come with a host of gastrointestinal adverse effects that patients may not be prepared to manage alone.
Managing “Class Action” Adverse Effects Crucial for GLP-1 Medication Adherence
Some patients may have difficulty managing the gastrointestinal adverse effects associated with GLP-1 therapies.
Pfizer Advances Oral GLP-1 Development as the Race for Second-Gen Obesity Therapies Continues
Pfizer joins Eli Lilly and Novo Nordisk in the development of oral GLP-1 receptor agonist candidates.
Head to Head Comparison of GLP-1 RAs for Weight Loss Tips Scales in Tirzepatide’s Favor
Previously, data from head-to-head trials of tirzepatide and semaglutide were not available.